DURHAM, N.C. , Aug.
21, 2024 /PRNewswire/ -- Leader in comprehensive real-world evidence (RWE) and advanced analytical solutions, Target RWE , will share new findings on a sequential nested trial (SNT) study at the International Society for Pharmacoepidemiology (ISPE) annual meeting from August 24-28 th in Berlin, Germany . Titled "Comparing causal estimands from a sequential nested trial emulation with a treatment decision design to a conventional single point randomized trial: A simulation study, " the research compared an SNT emulation that indexes patients at treatment decision points to a typical trial that randomizes patients once (known as a single-point trial or SPT). "Indexing patients at treatment decision points in SNT emulations can be an efficient approach to studying the effectiveness and safety of new treatments against a background standard of care.
Our study illuminates some challenges with the interpreting of such studies," said Target RWE Scientific Advisor, M. Alan Brookhart , PhD. "By accounting for differences in the patient visit process, it is possible to standardize results to improve their interpretability.
" The study, led by Chase Latour and Catie Wiener , used advanced Monte-Carlo simulation techniques that mirrored complex real-world clinical situations to assess the performance of different analytic techniques. "Our research at ISPE 2024 represents a significant step forward in understanding the sequential nested trial design," said Target RWE Ch.